|
May 20
|
Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22
|
|
May 15
|
Are Medical Stocks Lagging Atossa Genetics (ATOS) This Year?
|
|
May 14
|
Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen
|
|
Mar 28
|
All You Need to Know About Atossa Genetics (ATOS) Rating Upgrade to Buy
|
|
Mar 26
|
We Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business Growth
|
|
Mar 25
|
Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update
|
|
Mar 20
|
Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
|
|
Mar 11
|
Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications
|